ClinicalTrials.gg
RecruitingNCT07594379Updated Oct 21, 2026

Bronchoscopic Airway Clearance for Improving Lung Aeration in Mechanically Ventilated Patients With Atelectasis

An interventional study of Flexible Bronchoscopy-Guided Airway Clearance and Usual Airway Care in Atelectasis and Mechanical Ventilation, sponsored by Southeast University, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Southeast University, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 21, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Pulmonary Atelectasis with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Pulmonary Atelectasis · China.

Planned enrollment
7th of 21
104 · median 90
Started
2026
with 4 others
No phase
19 of 24
12 open now
Primary completion
2027-12
later than 10 of 13 live
Registered
22nd of 24
by date

Among the 24 studies in Pulmonary Atelectasis with a site in China, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2026, is one of 19 with no phase, reaches primary completion later than 10 of the 13 other live ones, and was the 22nd registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

13 of the 24 studies in Pulmonary Atelectasis with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Pulmonary Atelectasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether bedside flexible bronchoscopy-guided airway clearance can improve lung aeration in adult patients who are receiving invasive mechanical ventilation and have atelectasis with a high airway secretion burden.

The main questions it aims to answer are:

Does bedside flexible bronchoscopy-guided airway clearance reduce the proportion of nonaerated lung tissue from baseline to day 5? Does this treatment improve other lung aeration measures, respiratory mechanics, arterial blood gas parameters, pulmonary infection score, ventilator-free days, intensive care unit length of stay, and safety outcomes?

Researchers will compare usual airway care plus bedside flexible bronchoscopy-guided airway clearance with usual airway care alone to see if bronchoscopy-guided airway clearance improves lung aeration and clinical outcomes.

Participants will be randomly assigned to one of two groups. Participants in the usual care group will receive standard airway management, which may include airway suctioning, postural drainage, humidification, chest physiotherapy, and other routine respiratory care. Participants in the bronchoscopy group will receive the same usual care, plus bedside flexible bronchoscopy-guided airway clearance when predefined criteria for high airway secretion burden are met.

Participants will have clinical assessments during the study, including chest imaging, respiratory mechanics measurements, arterial blood gas tests, pulmonary infection score assessment, and safety monitoring. The main assessment will compare quantitative chest computed tomography findings at baseline and day 5 to evaluate changes in nonaerated lung tissue.

03

Conditions studied

  • Atelectasis
  • Mechanical Ventilation

Browse trials for

Keywords

  • Atelectasis
  • Mechanical Ventilation
  • Airway Secretion Retention
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Receiving invasive mechanical ventilation for at least 48 hours
  3. Presence of atelectasis confirmed by chest computed tomography, chest X-ray, or lung ultrasound
  4. High airway secretion burden, defined as requiring airway suctioning at least twice per hour during the previous 8 hours
  5. Written obtained from the participant or legally authorized representative

Exclusion criteria

Exclusion Criteria:

  1. Expected duration of artificial airway maintenance less than 5 days
  2. Untreated tension pneumothorax
  3. Large pleural effusions requiring thoracentesis.
  4. Known or suspected aspiration
  5. Active intrapulmonary hemorrhage
  6. Severe dysfunction of other organs with expected short-term mortality within 7 days or need for palliative care
  7. Any other condition judged by the medical team to make the participant unsuitable for the study
  8. not obtained
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    Usual Airway Care

    Other: Usual Airway Care

  • Experimental
    Bronchoscopy-Guided Airway Clearance

    Procedure: Flexible Bronchoscopy-Guided Airway Clearance

Interventions

  • ProcedureFlexible Bronchoscopy-Guided Airway Clearance

    Bedside flexible bronchoscopy-guided airway clearance will be performed through the artificial airway in mechanically ventilated participants. The procedure will be used to inspect the tracheobronchial tree and remove retained airway secretions or mucus plugs by targeted suctioning. Small-volume saline lavage may be used when secretions are thick or difficult to remove. The intervention will be performed in addition to usual airway care when predefined criteria for high airway secretion burden are met. After the procedure, ventilator settings will be restored according to the study protocol and the participant's clinical condition.

  • OtherUsual Airway Care

    Usual airway care may include airway suctioning, postural drainage, chest physiotherapy, mechanical airway clearance techniques, humidification and heating of inhaled gas, cuff pressure monitoring, and timely clearance of airway secretions according to routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Percent Change in CT-assessed Nonaerated Lung Percentage From Baseline to Day 5

    Time frame: Baseline to Day 5

Secondary outcomes

  1. Percent Change in CT-assessed Normally Aerated Lung Percentage From Baseline to Day 5

    Time frame: Baseline to Day 5, with chest CT performed within 24 hours of each time point

  2. Change in static respiratory system compliance from baseline to Day 5

    Static respiratory system compliance will be measured under controlled mechanical ventilation. The change from baseline to Day 5 will be calculated as the Day 5 value minus the baseline value.

    Time frame: Baseline to Day 5

  3. Change in driving pressure from baseline to Day 5

    Driving pressure will be calculated as plateau pressure minus positive end-expiratory pressure. The change from baseline to Day 5 will be calculated as the Day 5 value minus the baseline value.

    Time frame: Baseline and Day 5

  4. Change in plateau pressure from baseline to Day 5

    Plateau pressure will be recorded during mechanical ventilation. The change from baseline to Day 5 will be calculated as the Day 5 value minus the baseline value.

    Time frame: Baseline and Day 5

  5. Change in PaO2/FiO2 ratio from baseline to Day 5

    Time frame: Baseline and Day 5

  6. Ventilator-free days within 28 days after randomization

    Ventilator-free days are defined as the number of days alive and free from invasive mechanical ventilation during the first 28 days after randomization. Patients who die before Day 28 will be assigned zero ventilator-free days. Patients who remain on invasive mechanical ventilation for 28 days or longer will also be assigned zero ventilator-free days. For patients successfully liberated from invasive mechanical ventilation and alive at Day 28, ventilator-free days will be calculated as 28 minus the number of days receiving invasive mechanical ventilation.

    Time frame: From randomization to Day 28

  7. All-cause mortality within 28 days after randomization

    All-cause mortality will be defined as death from any cause occurring within 28 days after randomization.

    Time frame: From randomization to Day 28

  8. Length of stay in the intensive care unit

    Time frame: From randomization to ICU discharge or death, assessed up to 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 16 months is above that.

Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 18, 2026
StartActual
Aug 5, 2026was Jun 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 1, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
1 site added — first site in China
Show site
  • Zhongda Hospital, Southeast University · Nanjing, China
Oct 21, 2026
Start date
Jun 1, 2026→Aug 5, 2026 (actual)
Oct 21, 2026
Eligibility
1 exclusion criterion edited, 2 added
What changed in the criteria
Exclusion criteria
  • AddedUntreated tension pneumothorax
  • AddedLarge pleural effusions requiring thoracentesis.
  • EditedUntreated tension pneumothorax Known or suspected aspiration
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Zhongda Hospital, Southeast University · Nanjing, China
    Start date Jun 1, 2026→Aug 5, 2026 (now actual)
    Eligibility 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Exclusion criteria
    • AddedUntreated tension pneumothorax
    • AddedLarge pleural effusions requiring thoracentesis.
    • EditedUntreated tension pneumothorax Known or suspected aspiration

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07594379
Responsible party
Ling Liu (professor, Southeast University, China) — Principal investigator
First posted
May 18, 2026
Start date
Aug 5, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Mengyuan Shen, MD
Contact
Smy0116tu@163.com
+8615996997839
Ling Liu, PHD
principal investigator · Zhongda Hospital, School of Medicine, Southeast University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion